Parameter
| Biomarker | IL-6 | Full name | Interleukin-6 | Molecular Type | cell factor |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Systemic inflammation assessment and treatment monitoring | ||
| Disease | Rheumatoid Arthritis (RA) | Disease Subtypes | / | ||
| Organ | Joint (Synovium, Systemic) | Test Sample / Technology Platform | Serum, synovial fluid (ELISA, electrochemiluminescence assay) | ||
| Pathobiological Mechanisms | Mediates acute-phase reactions (e.g., CRP, SAA synthesis), promotes B-cell differentiation into plasma cells and autoantibody production, and participates in extra-articular manifestations. | ||||
| Clinical Availability Status | Widespread availability (assisted evaluation + target monitoring) | ||||
| Notes and Dynamics | IL-6 inhibitors (e.g., tocilizumab) rapidly reduce systemic inflammatory markers and demonstrate significant advantages in patients with rheumatoid arthritis (RA) who also have anemia or hypercoagulability. | ||||